SC
PGNX

Steven Cohen’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Steven Cohen’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,785,100
Closed -$14.1M – 1368
2019
Q3 		$14.1M Sell
2,785,100
-3,073,649
-52% -$15.3M 0.09% 283
2019
Q2 		$36.1M Buy
5,858,749
+58,749
+1% +$283K 0.19% 142
2019
Q1 		$26.9M Buy
5,800,000
+1,025,000
+21% +$4.64M 0.12% 194
2018
Q4 		$20.1M Buy
+4,775,000
New +$24.3M 0.1% 256

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Steven Cohen's PGNX Position: Q4 2019 in Review

Steven Cohen sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 2,785,100 shares — an estimated $14.1M sold.

Steven Cohen first reported a position in PGNX in Q4 2018 and held it in 4 quarters. The position peaked at $36.1M in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Steven Cohen reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Steven Cohen sold 2,785,100 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $14.1M.
  • Steven Cohen first reported a position in Progenics Pharmaceuticals Inc in Q4 2018 and held it in 4 quarters.
  • Steven Cohen's Progenics Pharmaceuticals Inc position peaked at $36.1M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.